ChimerixCMRX
CMRX
About: Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Employees: 72
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
6% more capital invested
Capital invested by funds: $32.5M [Q2] → $34.5M (+$2.03M) [Q3]
0.07% more ownership
Funds ownership: 41.33% [Q2] → 41.4% (+0.07%) [Q3]
13% less funds holding
Funds holding: 72 [Q2] → 63 (-9) [Q3]
32% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 19
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
68% less call options, than puts
Call options by funds: $50K | Put options by funds: $157K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
78%
upside
Avg. target
$8.50
152%
upside
High target
$11
226%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Edward White 28% 1-year accuracy 41 / 144 met price target | 226%upside $11 | Buy Reiterated | 30 Dec 2024 |
Wedbush David Nierengarten 34% 1-year accuracy 44 / 128 met price target | 78%upside $6 | Outperform Reiterated | 18 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility
Positive
Seeking Alpha
1 month ago
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diffuse midline glioma bolster confidence in FDA approval, despite potential timeline uncertainties. Financially, CMRX has a cash runway of 6–7 quarters, sufficient to reach an FDA decision, but risks of dilution remain.
Neutral
GlobeNewsWire
1 month ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma in the United States before year-end.
Neutral
GlobeNewsWire
1 month ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to three new employees of non-statutory stock options to purchase up to a total of 385,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
Neutral
Seeking Alpha
2 months ago
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen - Chief Scientific Officer Michelle LaSpaluto - Chief Financial Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen and welcome to the Chimerix Third Quarter 2024 Earnings Conference Call. I would now like to introduce you to your host for today's call, Will O'Connor from Stern Investor Relations.
Negative
Zacks Investment Research
2 months ago
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business overview.
Neutral
GlobeNewsWire
2 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 130,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
Neutral
GlobeNewsWire
4 months ago
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 150,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4).
Neutral
Seeking Alpha
5 months ago
Chimerix, Inc. (CMRX) Q2 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Mike Andriole - President and Chief Executive Officer Michelle LaSpaluto - Chief Financial Officer Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Tom Riga - Chief Operating and Commercial Officer Conference Call Participants Maury Raycroft - Jefferies Soumit Roy - Jones Research Ed White - HC Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Chimerix Second Quarter 2024 Earnings Conference Call.
Charts implemented using Lightweight Charts™